Oral LAT8881 in Neuropathic Pain

Status Completed

Clinical Trial Summary

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.

Clinical Trial Description

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain. After a one week baseline period, subjects entered into the study will be randomised to receive Investigational Medicinal Product (IMP) (LAT8881 or placebo) twice daily for four weeks. The first treatment period will be followed by a washout period of two weeks and then a second baseline period of one week. Subjects will not take any IMP over these three weeks. After the second baseline period, subjects will cross over to receive the second treatment (either LAT8881 or placebo, whichever treatment was not received in the first treatment period) twice daily for four weeks. The pharmacokinetics (PK) of LAT8881 will be investigated in 15 subjects (PK subjects) at selected Australian sites. ;

Study Design

Related Conditions & MeSH terms

Diabetic Peripheral Neuropathy (DPN)
Neuralgia
Neuralgia, Postherpetic
Neuropathic Pain
Peripheral Nervous System Diseases

Clinical Trial Details

NCT number	NCT03865953
Study type	Interventional
Source	Lateral Pharma Pty Ltd
Contact
Status	Completed
Phase	Phase 2
Start date	April 9, 2019
Completion date	May 3, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04699734` - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy	N/A
Recruiting	`NCT06019325` - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy	N/A
Completed	`NCT05235191` - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies	Phase 3
Completed	`NCT05845177` - Persistent Pain After Hip Replacement
Completed	`NCT05496205` - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT05949554` - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn	`NCT05052645` - Ear Acupuncture for Neuropathic Pain	N/A
Completed	`NCT02866396` - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Completed	`NCT02824588` - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain	N/A
Completed	`NCT02930551` - Neuromas as the Cause of Pain	N/A
Active, not recruiting	`NCT02560545` - Cannabinoids Effects on the Pain Modulation System	N/A
Enrolling by invitation	`NCT02485795` - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	N/A
Completed	`NCT02099890` - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury	Phase 3
Not yet recruiting	`NCT02246517` - The Effect of N2O on Chronic Neuropathic Pain Patients	Phase 0
Completed	`NCT01946555` - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain	N/A
Completed	`NCT01718821` - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients	N/A
Completed	`NCT01884662` - Virtual Walking for Neuropathic Pain in Spinal Cord Injury	N/A
Completed	`NCT01669967` - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin	N/A
Completed	`NCT01207596` - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain	Phase 4
Completed	`NCT01201317` - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy	Phase 2